Amarin's plan consists of seeking robust patent protection and regulatory exclusivity, maintaining trade secrets and taking advantage of manufacturing barriers to entry, with the goal of protecting the commercial potential of AMR101 until at least 2030. Amarin had previously disclosed that it is prosecuting a total 16 U.S. patent applications across 11 patent families. The actual number of patent applications and patent families has since grown due to the splitting of previously filed applications among multiple continuations and the filing of new applications seeking to cover what the company believes is additional patentable subject matter based on AMR101 clinical results." :theflyonthewall.com
I agree that the patent issue is an important one for the longer term success of the drug. But there's no way that this stock is not going to be a lot higher than this on approval. And there's still plenty of time for positive news on the patent front before the approval in July. I say it's oversold and will bounce nicely tomorrow. If a market correction gives me a still lower price, so much the better!
FDA approval does not equate stock price increase. I think AMRN approval will be a "sell on the news" event. A drug with a patent which lasts only 1-2 years is worthless, especially since AMRN does NOT have the capacity to go at it alone.